AbbVie/$ABBV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Ticker
$ABBV
Sector
Primary listing
NYSE
Employees
57,000
Headquarters
Website
AbbVie Metrics
BasicAdvanced
$438bn
70.05
$3.54
0.28
$6.74
2.79%
Price and volume
Market cap
$438bn
Beta
0.28
52-week high
$267.47
52-week low
$190.75
Average daily volume
6.1m
Dividend rate
$6.74
Financial strength
Current ratio
0.809
Quick ratio
0.49
Long term debt to equity
-1,062.075
Total debt to equity
-1,102.722
Dividend payout ratio (TTM)
189.83%
Interest coverage (TTM)
7.86%
Profitability
EBITDA (TTM)
30,796
Gross margin (TTM)
72.79%
Net profit margin (TTM)
9.80%
Operating margin (TTM)
35.53%
Effective tax rate (TTM)
27.39%
Revenue per employee (TTM)
$1,130,000
Management effectiveness
Return on assets (TTM)
10.51%
Return on equity (TTM)
-209.62%
Valuation
Price to earnings (TTM)
70.054
Price to revenue (TTM)
6.815
Price to book
-73.83
Price to tangible book (TTM)
-4.84
Price to free cash flow (TTM)
24.096
Free cash flow yield (TTM)
4.15%
Free cash flow per share (TTM)
10.291
Dividend yield (TTM)
2.72%
Forward dividend yield
2.79%
Growth
Revenue change (TTM)
10.39%
Earnings per share change (TTM)
68.54%
3-year revenue growth (CAGR)
4.75%
10-year revenue growth (CAGR)
10.03%
3-year earnings per share growth (CAGR)
-10.05%
10-year earnings per share growth (CAGR)
0.21%
3-year dividend per share growth (CAGR)
-16.79%
10-year dividend per share growth (CAGR)
11.89%
What the Analysts think about AbbVie
Analyst ratings (Buy, Hold, Sell) for AbbVie stock.
AbbVie Financial Performance
Revenues and expenses
AbbVie Earnings Performance
Company profitability
AbbVie News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.